Showing results (341-350 of 432) with videos related to

Sort By:
Pageof 44
Clinical Science (London, England : 1979)|April 7, 2019
Glutaminolysis and lipoproteins are key factors in late immune recovery in successfully treated HIV-infected patientsIsaac Rosado-Sánchez, Esther Rodríguez-Gallego, Joaquim Peraire, et al.
Plos One|December 22, 2006
Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohortFélix Gutierrez, Sergio Padilla, Mar Masiá, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 7, 2022
Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254Christoph D Spinner, Franco Felizarta, Giuliano Rizzardini, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|August 24, 2013
[Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]Antonio Javier Blasco, Josep M Llibre, José Ramón Arribas, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 11, 2024
Major cardiovascular events after COVID-19 in people with HIVRaquel Martín-Iguacel, Sergio Moreno-Fornés, Andreu Bruguera, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 25, 2012
[Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]Antonio Javier Blasco, José Ramón Arribas, Vicente Boix, et al.
Journal of the International AIDS Society|November 15, 2014
ACTG-HIV symptoms changes in patients switched to RPV/FTC/TDF due to previous intolerance to CART. Interim analysis of the PRO-STR studyDaniel Podzamczer, Nerea Rozas, Pere Domingo, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Frontiers in Medicine|July 7, 2023
Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort studyRaquel Martín-Iguacel, Mari Carmen Vazquez-Friol, Joaquin Burgos, et al.
Pageof 44